The Life Backup Plan safety and wellness app is a proactive safety and care platform that increases independence without ...

MANCHESTER, United Kingdom, June 18, 2025 (GLOBE NEWSWIRE) -- Following the roaring success of its annual winter Comedy Tour ...

AVMAPKI™ FAKZYNJA™ CO-PACK is approved for the treatment of adult patients with KRAS -mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. IBTROZI™ is ...

Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing is pleased to announce ...

OnlineSemaglutide.org exists to make evidence‑based GLP‑1 medications simple, safe, and affordable for adults who deserve modern weight‑care options. We combine expert clinical guidance with ...

Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced a ...

The Company has granted the underwriters an option, exercisable within 45 days from the date of the final prospectus, to purchase up to an additional 400,000 Ordinary Shares at the public offering ...

WINNIPEG, Manitoba, June 18, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) provides updates on its reorganizational phase.

Excellent Brain Ltd. Expands Global Reach with Spanish Neurofeedback Course ...

(NASDAQ: EYEN) (“Eyenovia” or the “Company”), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid ...

Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Body weight reductions of a mean of 11.6% after 28 weeks with ...

Eolo Pharma, a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, today announced the publication of its first-in-human study in Nature Metabolism, ...